Unfortunately HC posters don’t get to decide what trials are needed or what regulators should do!
whatever term you use - phase 3 or pivotal -it’ll be needed if they want US marketing approval by FDA for pancreatic cancer. it’ll probably also be needed to supply stronger data more likely to convince public health systems to pay for it and oncologists to use device.
SRX actually had large phase 3 programme, FOXFIRE.
And I don’t see “marketing spin” being a winning commercial strategy here.
Unfortunately HC posters don’t get to decide what trials are...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $16.66M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.5¢ | 0.5¢ | $6.396K | 1.279M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 600000 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 18270968 | 24 |
View Market Depth
| Last trade - 11.14am 19/06/2024 (20 minute delay) ? |
| OSL (ASX) Chart |